Results 141 to 150 of about 82,056 (314)

Evaluation of epidemiologic and demographic aspects of primary biliary cirrhosis in Isfahan population from 2009 - 2017

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2018
Introdution: Primary biliary cirrhosis is a chronic cholestatic disease of the liver, characterized by the inflammation plus progressive and non-purulent destruction of the small biliary ducts, and the presence of auto antibodies against mitochondrial ...
babak tamizi far, sayed mohamad javad sajadi, vahid sebghatollahi   +2 more
doaj  

Central blood volume in cirrhosis [PDF]

, 1993
Bendtsen, Flemming, Gerbes, Alexander L., Henriksen, Jens H.   +2 more
core   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu, Qinnian Li, Lagan Kumar Manandhar, Bilian Zhu, Chenrui Zhang, Weimin Bao, Yingmei Tang   +6 more
wiley   +1 more source

Global research trends in biliary atresia-related liver fibrosis: a bibliometric analysis (2000-2024). [PDF]

Front Pediatr
Zhang Y, Li B, Xia S, Wang T.
europepmc   +1 more source

Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study

Portal Hypertension &Cirrhosis, EarlyView.
CN‐TIPS is a nationwide, multicenter prospective registry that will enroll 10,000 adults with portal hypertension undergoing transjugular intrahepatic portosystemic shunt in China, integrating perioperative clinical and hemodynamic metrics with standardized imaging (including computational modeling in a dedicated subcohort) and multi‐omics biospecimens,
Yi Xiang, Yong Lv, Hongwei Zhou, Jianbo Zhao, Meng Niu, Jiacheng Liu, Guangchuan Wang, Qi Zhang, Weizhong Zhou, Beijia Yu, Jun Chi, Guo Han, Jiawei Zhang, Long Gao, Wenjing Liu, Zhang Zhang, Tianyu Liu, Wuhua Guo, He Zhao, Gao‐Jun Teng, Xiaolong Qi   +20 more
wiley   +1 more source

Role of Liver Biopsy in Biliary Atresia: Impact of Histological Fibrosis on Kasai Portoenterostomy Outcomes and Decision Making. [PDF]

Pediatr Gastroenterol Hepatol Nutr
Al Lawati TT, Saadah O, Al Sajwani MJ, Al Lawati FAR.   +3 more
europepmc   +1 more source

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC [PDF]

Liver Int
ABSTRACT Background Portal vein thrombosis (PVT) is a common sequela of cirrhosis. Despite regression of fibrosis/cirrhosis observed among some patients after disease‐specific treatment, few studies have considered the role of treatment and response on risk of PVT among patients with cirrhosis across different liver disease states.
Gonzalez H, Gordon S, Trudeau S, Wu T, Rupp L, Melkonian C, Schmidt M, Daida Y, Sahota A, Bowlus C, Lu M.   +10 more
europepmc   +2 more sources

Clinical liver transplantation [PDF]

, 1969
Brettschneider, L, Giles, G, Penn, I, Picache, R, Putnam, CW, Starzl, TE   +5 more
core   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source